Literature DB >> 26290246

Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.

Suresh D Muthukumaraswamy1, Alexander D Shaw2, Laura E Jackson3, Judith Hall3, Rosalyn Moran4, Neeraj Saxena5.   

Abstract

Following the discovery of the antidepressant properties of ketamine, there has been a recent resurgence in the interest in this NMDA receptor antagonist. Although detailed animal models of the molecular mechanisms underlying ketamine's effects have emerged, there are few MEG/EEG studies examining the acute subanesthetic effects of ketamine infusion in man. We recorded 275 channel MEG in two experiments (n = 25 human males) examining the effects of subanesthetic ketamine infusion. MEG power spectra revealed a rich set of significant oscillatory changes compared with placebo sessions, including decreases in occipital, parietal, and anterior cingulate alpha power, increases in medial frontal theta power, and increases in parietal and cingulate cortex high gamma power. Each of these spectral effects demonstrated their own set of temporal dynamics. Dynamic causal modeling of frontoparietal connectivity changes with ketamine indicated a decrease in NMDA and AMPA-mediated frontal-to-parietal connectivity. AMPA-mediated connectivity changes were sustained for up to 50 min after ketamine infusion had ceased, by which time perceptual distortions were absent. The results also indicated a decrease in gain of parietal pyramidal cells, which was correlated with participants' self-reports of blissful state. Based on these results, we suggest that the antidepressant effects of ketamine may depend on its ability to change the balance of frontoparietal connectivity patterns. SIGNIFICANCE STATEMENT: In this paper, we found that subanesthetic doses of ketamine, similar to those used in antidepressant studies, increase anterior theta and gamma power but decrease posterior theta, delta, and alpha power, as revealed by magnetoencephalographic recordings. Dynamic causal modeling of frontoparietal connectivity changes with ketamine indicated a decrease in NMDA and AMPA-mediated frontal-to-parietal connectivity. AMPA-mediated connectivity changes were sustained for up to 50 min after ketamine infusion had ceased, by which time perceptual distortions were absent. The results also indicated a decrease in gain of parietal pyramidal cells, which was correlated with participants' self-reports of blissful state. The alterations in frontoparietal connectivity patterns we observe here may be important in generating the antidepressant response to ketamine.
Copyright © 2015 the authors 0270-6474/15/3511695-13$15.00/0.

Entities:  

Keywords:  alpha rhythms; depression; dynamic causal modelling; gamma rhythms; ketamine; magnetoencephalography

Mesh:

Substances:

Year:  2015        PMID: 26290246      PMCID: PMC4540803          DOI: 10.1523/JNEUROSCI.0903-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  69 in total

Review 1.  Distributed hierarchical processing in the primate cerebral cortex.

Authors:  D J Felleman; D C Van Essen
Journal:  Cereb Cortex       Date:  1991 Jan-Feb       Impact factor: 5.357

2.  Ketamine for treatment-resistant depression: ready or not for clinical use?

Authors:  A John Rush
Journal:  Am J Psychiatry       Date:  2013-10       Impact factor: 18.112

3.  Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.

Authors:  Jesse Wood; Yunbok Kim; Bita Moghaddam
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

Review 4.  Signaling pathways underlying the rapid antidepressant actions of ketamine.

Authors:  Ronald S Duman; Nanxin Li; Rong-Jian Liu; Vanja Duric; George Aghajanian
Journal:  Neuropharmacology       Date:  2011-09-02       Impact factor: 5.250

5.  Comparing families of dynamic causal models.

Authors:  Will D Penny; Klaas E Stephan; Jean Daunizeau; Maria J Rosa; Karl J Friston; Thomas M Schofield; Alex P Leff
Journal:  PLoS Comput Biol       Date:  2010-03-12       Impact factor: 4.475

6.  Disruption of frontal-parietal communication by ketamine, propofol, and sevoflurane.

Authors:  UnCheol Lee; SeungWoo Ku; GyuJeong Noh; SeungHye Baek; ByungMoon Choi; George A Mashour
Journal:  Anesthesiology       Date:  2013-06       Impact factor: 7.892

Review 7.  mTOR complexes in neurodevelopmental and neuropsychiatric disorders.

Authors:  Mauro Costa-Mattioli; Lisa M Monteggia
Journal:  Nat Neurosci       Date:  2013-10-28       Impact factor: 24.884

8.  HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine.

Authors:  Xiangdong Chen; Shaofang Shu; Douglas A Bayliss
Journal:  J Neurosci       Date:  2009-01-21       Impact factor: 6.167

9.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  Broadband cortical desynchronization underlies the human psychedelic state.

Authors:  Suresh D Muthukumaraswamy; Robin L Carhart-Harris; Rosalyn J Moran; Matthew J Brookes; Tim M Williams; David Errtizoe; Ben Sessa; Andreas Papadopoulos; Mark Bolstridge; Krish D Singh; Amanda Feilding; Karl J Friston; David J Nutt
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

View more
  69 in total

Review 1.  Neural Correlates of Unconsciousness in Large-Scale Brain Networks.

Authors:  George A Mashour; Anthony G Hudetz
Journal:  Trends Neurosci       Date:  2018-02-03       Impact factor: 13.837

2.  Pharmaco-electroencephalographic responses in the rat differ between active and inactive locomotor states.

Authors:  Ingeborg H Hansen; Claus Agerskov; Lars Arvastson; Jesper F Bastlund; Helge B D Sørensen; Kjartan F Herrik
Journal:  Eur J Neurosci       Date:  2019-04-01       Impact factor: 3.386

3.  Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.

Authors:  Jessica R Gilbert; Elizabeth D Ballard; Christina S Galiano; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-03

4.  Electroencephalogram signatures of ketamine anesthesia-induced unconsciousness.

Authors:  Oluwaseun Akeju; Andrew H Song; Allison E Hamilos; Kara J Pavone; Francisco J Flores; Emery N Brown; Patrick L Purdon
Journal:  Clin Neurophysiol       Date:  2016-03-16       Impact factor: 3.708

5.  Network-level Mechanisms of Ketamine Anesthesia.

Authors:  George A Mashour
Journal:  Anesthesiology       Date:  2016-11       Impact factor: 7.892

6.  Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers.

Authors:  Andria Pelentritou; Levin Kuhlmann; John Cormack; Will Woods; Jamie Sleigh; David Liley
Journal:  J Vis Exp       Date:  2018-01-13       Impact factor: 1.355

7.  Connectomic Underpinnings of Working Memory Deficits in Schizophrenia: Evidence From a replication fMRI study.

Authors:  Jie Yang; Weidan Pu; Guowei Wu; Eric Chen; Edwin Lee; Zhening Liu; Lena Palaniyappan
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 8.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 9.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

Review 10.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Authors:  Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2016-05-12       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.